Here’s a fact about severe aortic stenosis: 1 in 10 symptomatic patients may die within 5 weeks without intervention.* For more of the latest data on managing severe AS, visit us at Booth #3736 at #AHA25.

Don't miss the last webinar in the series 'Optimizing Valvular Heart Disease Patient Care: Evidence-Based Insights from Multidisciplinary Teams' on November 12! Register Here: https://t.co/osot62lhzf From exploring enhanced outcomes through multidisciplinary collaboration to

#AHA25 is almost here! Connect with us at Booth #3736 for the latest evidence-based approaches on when to act when managing severe aortic stenosis, patient cases that highlight the broadened eligibility of TAVR, and much more. Secure your spot at #AHA25 today.

Join us on November 12 for a one-hour practical session on the evolving role of valvular heart disease in everyday cardiology practice: https://t.co/nsFK0bp6lB The program covers: • The role of valvular heart disease in general cardiology • How to apply clinical reasoning to

The latest 7-year PARTNER 3 Trial data is here. #PARTNER3Trial #PARTNER3 #SAPIEN3TAVR See the data: https://t.co/o9tYv5B8ED ⚠️Important Safety Info: https://t.co/MI0Ets6xEQ

The latest 7-year PARTNER 3 Trial data is here. #PARTNER3Trial #PARTNER3 #SAPIEN3TAVR See the data: https://t.co/sgxG3MtvWE ⚠️ Important Safety Info: https://t.co/nfiz6FRwTo

Join us for peer-to-peer discussions on streamlining the aortic stenosis patient pathway, the evolving treatment landscape, and more at our sponsored symposia. Reserve your spot now: https://t.co/BIkQvKIqFJ

~50% of severe AS patients don’t recognize/report symptoms. Linda was 1 of them. She “felt fine,” but 1 visit w/ her doctor led to a lifesaving diagnosis. Her story reinforces the crucial need for routine screening & prompt referral to a Heart Valve Team: https://t.co/73AY7vppOQ

Severe aortic stenosis is unpredictable & life-threatening. An @AmericanHeartJ study found that pts evaluated by a heart valve team member had significantly ⬇️risk of death, reinforcing the need for prompt referral upon diagnosis. Explore AVR eligibility: https://t.co/OmpPpqnLdp

When it comes to severe AS, you are your pts' 1st line of defense. Your commitment to routine screening+prompt referral saves lives, & that deserves recognition. Join us this World Heart Day to celebrate all you do to help create a 🫀valve healthy future: https://t.co/7eFEpOyHPy

🚨 UPDATE: New 2025 ASE Guidelines now classify new or acute severe AS as a critical finding, representing a threat to life and requiring immediate clinical action. Explore data that reinforce the urgent need for prompt referral upon severe AS diagnosis: https://t.co/JSM8zrlHEk

ICYMI: The ESC has new treatment guidance for asymp severe AS pts. Since ACC/AHA already recommends referring for eval when treatment is considered, these guidelines for Europe add to robust evidence supporting prompt AVR in severe AS pts. Learn more: https://t.co/yRtqswjI9k

Edwards SAPIEN 3 TAVR is the leading TAVR choice in the U.S., backed by lifesaving outcomes. It delivers the lowest 5-year mortality rate in any TAVR pivotal trial. #TAVR #SAPIEN3TAVR https://t.co/ojNU1JGDFM

Severe AS can progress rapidly and unpredictably, even under clinical surveillance. Explore data that reinforce the need for prompt referral upon diagnosis: https://t.co/X3B65lmzv3

Symptom onset can occur rapidly and unpredictably. Referring your patients to a Heart Valve Team immediately upon diagnosis can be lifesaving. Learn more about the crucial need to refer severe AS patients for evaluation upon diagnosis: https://t.co/qHefNZRXNH

Check out the most recent episode from the TAVR Now series! Brian Lindman, @SammyElmariahMD, and David Wood discuss their experiences with implementing echo alerts to assist with patient management. Listen here: https://t.co/jVXLz0ChSx

Don’t wait until symptom onset to take action—refer your severe AS patients to a Heart Valve Team for evaluation upon diagnosis for a chance at lifesaving outcomes. Find your Heart Valve Team today: https://t.co/7ycl9f5MvH

Edwards SAPIEN 3 Ultra RESILIA valve: the #1 TAVR choice in the U.S. is now approved for asymptomatic severe AS. Only prompt intervention with SAPIEN 3 TAVR is proven superior* to clinical surveillance. #TAVRbyEdwards https://t.co/CGFlfuok4M

Are we only halfway there getting patients to treatment? Data show over 50% of eligible patients don’t receive AVR. I’m highlighting how we can confront this critical health issue through multidisciplinary partnership with @EdwardsLifesci https://t.co/vtPDcfiQyY

Are we referring severe aortic stenosis patients at the right time? Data continue to suggest they can't afford to wait. I'm collaborating with @EdwardsLifesci on the benefit of a Heart Valve Team approach for managing these patients, regardless of symptoms. #hearthealth #cardioEd